Amendment 2 to Grant Agreement, dated February 26, 2025, by and between Decoy Therapeutics, Inc. and The Gates Foundation (formerly known as the Bill & Melinda Gates Foundation)
EX-10.28 4 exhibit1028-sx1a.htm EX-10.28 Document
Exhibit 10.28
Gates Foundation
AMENDMENT 2
to
GRANT AGREEMENT
Investment ID INV-027470
AMENDMENT SUMMARY PAGE
| AMENDMENT INFORMATION | |||||
Agreement to be Amended: | Grant agreement between the Gates Foundation, formerly known as the Bill & Melinda Gates Foundation, and Decoy Therapeutics, Inc, effective September 9, 2021, as amended, and bearing Investment ID INV-027470 | ||||
Amendment Purpose: | No cost extension | ||||
| “Amendment Date” | February 26, 2025 | ||||
| Amended “End Date”: | The term of the Agreement is extended by changing the End Date to February 28,2026 | ||||
THIS AMENDMENT amends, and is made part of, the above-referenced Agreement and is effective as of the Amendment Date. Capitalized terms not defined in this Amendment will have the meaning provided in the Agreement. Except as modified by this Amendment, all other terms and conditions of the Agreement remain in full force and effect. In the event of a conflict between the Agreement and this Amendment, the terms of this Amendment will prevail.
REPORTING & PAYMENT SCHEDULE
This Amendment notifies You that the reporting and/or payment schedule for Your grant has changed. Your Reporting & Payment Schedule is deleted and replaced with the following:
| REPORTING & PAYMENT SCHEDULE | |||||||||||||||||||||||
| Investment Period | Target, Milestone, or Reporting Deliverable | Due By | Payment Date | Payment Amount (U.S.$) | |||||||||||||||||||
| Countersigned Agreement | COMPLETE | September 9, 2021 | $480,400.00 | ||||||||||||||||||||
| Milestone 1 - Utility of DCOY101 as a pre and/or post-infection therapeutic | COMPLETE | August 2, 2022 | $424,244.00 | ||||||||||||||||||||
| Start Date to December 31, 2021 | Progress Report | COMPLETE | |||||||||||||||||||||
| January 1,2022 to December 31,2022 | Progress Report | COMPLETE | |||||||||||||||||||||
| Countersigned Agreement | COMPLETE | August 30, 2023 | $3,500,000.00 | ||||||||||||||||||||
| January 1,2023 to December 31,2023 | Progress Report | COMPLETE | March 2025 | $584,500.00 | |||||||||||||||||||
| Global Access Strategy/Commitment | RECEIVED | ||||||||||||||||||||||
| January 1,2024 to December 31,2024 | Progress Report | March 31,2025 | |||||||||||||||||||||
| January 1,2025 to December 31,2025 | Progress Report | March 31,2026 | |||||||||||||||||||||
| Start Date to End Date | Final Report | Within 60 days of End Date | |||||||||||||||||||||
| Amended Total Grant Amount | $4,989,144.00 | ||||||||||||||||||||||
As provided in the Agreement, signatures are not required.
| Investment ID INV-027470 | 1 of 1 | Version: August 2022 | |||||||||
